Studies on the interactions between C-reactive protein and complement proteins

Immunology

Volumn 121, Issue 1, 2007, Pages 40-50

  Bíró, Adrienn ^a,d   Rovó, Zita ^a   Papp, Diana ^a   Cervenak, László ^b   Varga, Lilian ^a   Füst, George ^a,b   Thielens, Nicole M ^c   Arlaud, Gérard J ^c   Prohászka, Zoltán ^a,b  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c INSTITUT DE BIOLOGIE STRUCTURALE   (France)

^d NONE   (Hungary)

Author keywords

C reactive protein; C4b binding protein; Complement; Factor H; Inflammation

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4B BINDING PROTEIN; COMPLEMENT FACTOR H; PHOSPHORYLCHOLINE; REGULATOR PROTEIN; UREA;

ARTICLE; BINDING SITE; COMPLEMENT ACTIVATION; COMPLEX FORMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; SURFACE PLASMON RESONANCE;

C-REACTIVE PROTEIN; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; COMPLEMENT C4B-BINDING PROTEIN; COMPLEMENT FACTOR H; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34047230766     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2007.02535.x     Document Type: Article

References (40)

1. Volanakis JE. Human C-reactive protein. Expression, structure and function. Mol Immunol 2001; 38:189-97.
2. Pepys MB. C-reactive protein fifty years on. Lancet 1981; 1 (8221):653-7.
3. Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res 2004; 30:261-77.
4. Wu Y, Wang HW, Ji SR, Sui SF. Two-dimensional crystallization of rabbit C-reactive protein monomeric subunits. Acta Crystallogr D Biol Crystallogr 2003; 59:922-6.
5. Kresl JJ, Potempa LA, Anderson BE. Conversion of native oligomeric to a modified monomeric form of human C-reactive protein. Int J Biochem Cell Biol 1998; 30:1415-26.
6. Potempa LA, Maldonado BA, Laurent P, Zemel ES, Gewurz H. Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium. Mol Immunol 1983; 20:1165-75.
7. Ying SC, Gewurz H, Kinoshita CM, Potempa LA, Siegel JN. Identification and partial characterization of multiple native and neoantigenic epitopes of human C-reactive protein by using monoclonal antibodies. J Immunol 1989; 143:221-8.
8. Potempa LA, Zeller JM, Fiedel BA, Kinoshita CM, Gewurz H. Stimulation of human neutrophils, monocytes, and platelets by modified C-reactive protein (CRP) expressing a neoantigenic specificity. Inflammation 1988; 12:391-405.
9. Ji SR, Wu Y, Potempa LA, Qiu Q, Zhao J. Interactions of C-reactive protein with low-density lipoproteins: implications for an active role of modified C-reactive protein in atherosclerosis. Int J Biochem Cell Biol 2006; 38:648-61.
10. Ji SR, Wu Y, Potempa LA, Liang YH, Zhao J. Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2006; 26:935-41.
11. Gewurz H, Mold C, Siegel J, Fiedel B. C-reactive protein and the acute phase response. Adv Intern Med 1982; 27:345-72.
12. Kaplan MH, Volanakis JE. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 1974; 112:2135-47.
13. Volanakis JE, Kaplan MH. Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J Immunol 1974; 113:9-17.
14. McGrath FD, Brouwer MC, Arlaud GJ, Daha MR, Hack CE, Roos A. Evidence that complement protein C1q interacts with C-reactive protein through its globular head region. J Immunol 2006; 176:2950-7.
15. Sjoberg AP, Trouw LA, McGrath FD, Hack CE, Blom AM. Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of c4b-binding protein. J Immunol 2006; 176:7612-20.
16. Claus DR, Siegel J, Petras K, Osmand AP, Gewurz H. Interactions of C-reactive protein with the first component of human complement. J Immunol 1977; 119:187-92.
17. Berman S, Gewurz H, Mold C. Binding of C-reactive protein to nucleated cells leads to complement activation without cytolysis. J Immunol 1986; 136:1354-9.
18. Mold C, Gewurz H. Inhibitory effect of C-reactive protein on alternative C pathway activation by liposomes and Streptococcus pneumoniae. J Immunol 1981; 127:2089-92.
19. Mold C, Kingzette M, Gewurz H. C-reactive protein inhibits pneumococcal activation of the alternative pathway by increasing the interaction between factor H and C3b. J Immunol 1984; 133:882-5.
20. Suankratay C, Mold C, Zhang Y, Potempa LA, Lint TF, Gewurz H. Complement regulation in innate immunity and the acutephase response: inhibition of mannan-binding lectin-initiated complement cytolysis by C-reactive protein (CRP). Clin Exp Immunol 1998; 113:353-9.
21. Jarva H, Jokiranta TS, Hellwage J, Zipfel PF, Meri S. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol 1999; 163:3957-62.
22. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999; 42:23-30.
23. Li SH, Szmitko PE, Weisel RD, Wang CH, Fedak PW, Li RK, Mickle DA, Verma S. C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation 2004; 109:833-6.
24. Khreiss T, Jozsef L, Hossain S, Chan JS, Potempa LA, Filep JG. Loss of pentameric symmetry of C-reactive protein is associated with delayed apoptosis of human neutrophils. J Biol Chem 2002; 277:40775-81.
25. Arlaud GJ, Sim RB, Duplaa AM, Colomb MG. Differential elution of Clq, Clr and Cls from human Cl bound to immune aggregates. Use in the rapid purification of Cl subcomponents. Mol Immunol 1979; 16:445-50.
26. Tenner AJ, Lesavre PH, Cooper NR. Purification and radiolabeling of human C1q. J Immunol 1981; 127:648-53.
27. Arlaud GJ, Villiers CL, Chesne S, Colomb MG. Purified proenzyme C1r. Some characteristics of its activation and subsequent proteolytic cleavage. Biochim Biophys Acta 1980; 616:116-29.
28. Tacnet-Delorme P, Chevallier S, Arlaud GJ. Beta-amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for A beta on the C1q globular regions. J Immunol 2001; 167:6374-81.
29. Rossi V, Bally I, Thielens NM, Esser AF, Arlaud GJ. Baculovirusmediated expression of truncated modular fragments from the catalytic region of human complement serine protease C1s. Evidence for the involvement of both complement control protein modules in the recognition of the C4 protein substrate. J Biol Chem 1998; 273:1232-9.
30. Bíró A, Thielens NM, Cervenák L, Prohászka Z, Füst G, Arlaud GJ. Modified low density lipoproteins differentially bind and activate the C1 complex of complement. Mol Immunol 2007; 44:1169-77.
31. Schwedler SB, Guderian F, Dammrich J, Potempa LA, Wanner C. Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. Nephrol Dial Transplant 2003; 18:2300-7.
32. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18:1386-92.
33. Vaith P, Potempa LA. Deposition of modified or native C-reactive protein in atherosclerotic arteries? Arterioscler Thromb Vasc Biol 2000; 20:1173-4.
34. Giannakis E, Male DA, Ormsby RJ, Mold C, Jokiranta TS, Ranganathan S, Gordon DL. Multiple ligand binding sites on domain seven of human complement factor H. Int Immunopharmacol 2001; 1:433-43.
35. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190:1733-40.
36. Gill R, Kemp JA, Sabin C, Pepys MB. Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J Cereb Blood Flow Metab 2004; 24:1214-8.
37. Barnum SR, Dahlback B. C4b-binding protein, a regulatory component of the classical pathway of complement, is an acutephase protein and is elevated in systemic lupus erythematosus. Complement Inflamm 1990; 7:71-7.
38. Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, Meijer CJ, Hack CE. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997; 95:97-103.
39. Baidoshvili A, Nijmeijer R, Lagrand WK, Hack CE, Niessen HW. Localisation of C reactive protein in infarcted tissue sites of multiple organs during sepsis. J Clin Pathol 2002; 55:152-3.
40. Oksjoki R, Jarva H, Kovanen PT, Laine P, Meri S, Pentikainen MO. Association between complement factor H and proteoglycans in early human coronary atherosclerotic lesions: implications for local regulation of complement activation. Arterioscler Thromb Vasc Biol 2003; 23:630-6.